Neuroectodermal Tumors, Primitive
7 clinical trials · Condition
◉ Watch Neuroectodermal Tumors, Primitive
| Record | Firm | Date |
|---|---|---|
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (NCT04541082) | Jazz Pharmaceuticals | 2020-10-26 |
| HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors (NCT03911388) | M.D. Anderson Cancer Center | 2019-09-12 |
| Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (NCT02624388) | University of Virginia | 2016-08-01 |
| NAC to Prevent Cisplatin-induced Hearing Loss (NCT02094625) | Children's Hospital Los Angeles | 2016-03-01 |
| Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs (NCT02332889) | University of Louisville | 2015-04-01 |
| Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (NCT01661400) | Washington University School of Medicine | 2012-10-26 |
| High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood (NCT00180791) | Gustave Roussy, Cancer Campus, Grand Paris | 2002-07-01 |
Track Neuroectodermal Tumors, Primitive automatically
Every clearance here is in the API, with alerts when new ones post.